Bactericidal Activities of Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Aerobic and Anaerobic Respiratory Pathogens in Serum
Open Access
- 1 April 2003
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (4) , 1308-1312
- https://doi.org/10.1128/aac.47.4.1308-1312.2003
Abstract
Gatifloxacin (Bristol-Myers Squibb) and moxifloxacin (Bayer) are new methoxyfluoroquinolones with broad-spectrum activity against aerobic and anaerobic pathogens of the respiratory tract. In this investigation, we analyzed the bactericidal activity in serum over time of these antimicrobials against three aerobic ( Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus ) and four anaerobic ( Peptostreptococcus micros, Peptostreptococcus magnus, Fusobacterium nucleatum, and Prevotella melaninogenica ) bacteria associated with respiratory tract infections. Serum samples were obtained from 11 healthy male subjects following a single 400-mg oral dose of gatifloxacin and moxifloxacin. These samples were collected prior to and at 2, 6, 12, and 24 h after the dose of each drug. Gatifloxacin exhibited bactericidal activity for a median of 12 h against Streptococcus pneumoniae (MIC = 0.5 μg/ml), Peptostreptococcus micros (MIC = 0.25 μg/ml), and F. nucleatum (MIC = 0.5 μg/ml) and 24 h against H. influenzae (MIC = 0.03 μg/ml), Staphylococcus aureus (MIC = 0.125 μg/ml), Peptostreptococcus magnus (MIC = 0.125 μg/ml), and Prevotella melaninogenica (MIC = 0.5 μg/ml). Moxifloxacin exhibited bactericidal activity for a median of 24 h against Streptococcus pneumoniae (MIC = 0.125 μg/ml), H. influenzae (MIC = 0.015 μg/ml), Staphylococcus aureus (MIC = 0.06 μg/ml), F. nucleatum (MIC = 0.5 μg/ml), Prevotella melaninogenica (MIC =0.5 μg/ml), Peptostreptococcus magnus (MIC = 0.125 μg/ml), and Peptostreptococcus micros (MIC = 0.25 μg/ml). The results from this pharmacodynamic study suggest that these fluoroquinolones would have prolonged killing activity against these organisms in vivo and may have clinical utility in the treatment of mixed aerobic-anaerobic respiratory tract infections.Keywords
This publication has 30 references indexed in Scilit:
- Evaluation of Survival and Pharmacodynamic Relationships for Five Fluoroquinolones in a Neutropenic Murine Model of Pneumococcal Lung InfectionPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002
- Influence of the decrease in ciprofloxacin susceptibility and the presence of human serum on the in vitro susceptibility of Streptococcus pneumoniae to five new quinolonesJournal of Antimicrobial Chemotherapy, 2001
- Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapyJournal of Antimicrobial Chemotherapy, 2001
- Use of Modeling Techniques to Aid in Antibiotic Selection.Current Infectious Disease Reports, 2001
- Gatifloxacin, an Advanced 8‐Methoxy FluoroquinolonePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
- Comparative Activity of Moxifloxacin in Vitro Against Obligately Anaerobic BacteriaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2000
- Expanded activity and utility of the new fluoroquinolones: A reviewClinical Therapeutics, 1999
- Trovafloxacin: An OverviewPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1999
- Activities of Gatifloxacin Compared to Those of Seven Other Agents against Anaerobic OrganismsAntimicrobial Agents and Chemotherapy, 1998
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998